These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35670141)

  • 1. Triptan medication use among patients with migraine with contraindications in the US.
    Pero A; Pace A; Dhamoon MS
    Headache; 2022 Jul; 62(7):883-889. PubMed ID: 35670141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
    Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
    Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.
    Chen TB; Chen YT; Fuh JL; Tang CH; Wang SJ
    J Headache Pain; 2014 Aug; 15(1):48. PubMed ID: 25117594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-five years of triptans - a nationwide population study.
    Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
    Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
    Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology, Demographics, Triptan Contraindications, and Prescription Patterns of Patients with Migraine: A German Claims Database Study.
    Gendolla A; Rauer N; Kraemer S; Schwerdtner I; Straube A
    Neurol Ther; 2022 Mar; 11(1):167-183. PubMed ID: 34837636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
    Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
    Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
    Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
    Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
    Rapoport AM; Freitag F; Pearlman SH
    CNS Drugs; 2010 Nov; 24(11):929-40. PubMed ID: 20932065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
    Perearnau P; Vuillemet F; Schick J; Weill G
    Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
    Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
    PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence.
    Rothrock JF; Cady RK; Aurora SK; Brandes JL; Myers JA; Fox AW; Farr SJ
    Curr Med Res Opin; 2011 Nov; 27(11):2185-91. PubMed ID: 21942531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.